

Steven E Arnold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6935057/publications.pdf>

Version: 2024-02-01

69
papers

4,031
citations

361045

20
h-index

214527

47
g-index

84
all docs

84
docs citations

84
times ranked

6157
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns and Persistence of Perioperative Plasma and Cerebrospinal Fluid Neuroinflammatory Protein Biomarkers After Elective Orthopedic Surgery Using SOMAscan. <i>Anesthesia and Analgesia</i> , 2023, 136, 163-175.	1.1	6
2	Plasma IL-12/IFN- β axis predicts cognitive trajectories in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 645-653.	0.4	39
3	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. <i>Brain Pathology</i> , 2022, 32, e13035.	2.1	15
4	Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. <i>JCI Insight</i> , 2022, 7, .	2.3	11
5	Detection of Oculomotor Dysmetria From Mobile Phone Video of the Horizontal Saccades Task Using Signal Processing and Machine Learning Approaches. <i>IEEE Access</i> , 2022, 10, 34022-34031.	2.6	4
6	A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer's Disease. <i>Metabolites</i> , 2022, 12, 181.	1.3	5
7	Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. <i>JAMA Neurology</i> , 2022, 79, 478.	4.5	35
8	Proteomic characterization of post-mortem human brain tissue following ultracentrifugation-based subcellular fractionation. <i>Brain Communications</i> , 2022, 4, .	1.5	3
9	Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 58.	3.0	18
10	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, .	1.5	11
11	<i>GF2R</i> circular RNA hsa_circ_0131235 expression in the middle temporal cortex is associated with AD pathology. <i>Brain and Behavior</i> , 2021, 11, e02048.	1.0	12
12	Brain insulin signaling and cerebrovascular disease in human postmortem brain. <i>Acta Neuropathologica Communications</i> , 2021, 9, 71.	2.4	11
13	Plasma and cerebrospinal fluid inflammation and the blood-brain barrier in older surgical patients: the Role of Inflammation after Surgery for Elders (RISE) study. <i>Journal of Neuroinflammation</i> , 2021, 18, 103.	3.1	17
14	Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. <i>Neurobiology of Aging</i> , 2021, 105, 99-114.	1.5	32
15	VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. <i>Brain Communications</i> , 2021, 3, fcab261.	1.5	35
16	Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120023.	0.3	27
17	The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17656-17689.	2.9	28
18	Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood-based biomarker discovery. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Altered brain functional connectivity and cardiovascular and metabolic risk factors in middle-aged and older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
20	Active deep learning to detect cognitive concerns in electronic health records. <i>Alzheimer's and Dementia</i> , 2021, 17, e055362.	0.4	1
21	Matrix metalloproteinase-10 as a novel biomarker of neurodegeneration in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
22	The technical reliability and stability of ATN quantification using the Fujirebio Lumipulse G1200 fully-automated immunoassay instrument in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
23	Characterizing proteoforms of the granin family of neuropeptides in dementia pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, e056265.	0.4	0
24	Using cerebrospinal fluid ATN quantification to classify research subjects in a diverse clinical population. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
25	A comparison of multiple platforms for quantifying ATN values in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
26	Levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
27	Brain insulin signaling in persons with and without diabetes is associated with cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
28	Characterization of novel neuropeptide proteolytic processing involved in dementia pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, e058553.	0.4	0
29	Brain insulin signaling and cerebrovascular disease in human postmortem brain.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052253.	0.4	0
30	Senior Moments or More? Diagnostic Evaluation of Cognitive Complaints in Older Adults and the Role of Cerebrospinal Fluid Biomarkers. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 219-224.	0.6	1
31	Apolipoprotein E genotype and the association between C-reactive protein and postoperative delirium: Importance of gene-protein interactions. <i>Alzheimer's and Dementia</i> , 2020, 16, 572-580.	0.4	21
32	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 575953.	1.1	45
33	The Role of Inflammation after Surgery for Elders (RISE) study: Examination of [11C]PBR28 binding and exploration of its link to post-operative delirium. <i>NeuroImage: Clinical</i> , 2020, 27, 102346.	1.4	17
34	A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. <i>Trials</i> , 2020, 21, 1016.	0.7	0
35	Apolipoprotein E genotype and the relationship between chitinase 3-like protein 1 and postoperative delirium: Potential gene-protein interactions. <i>Alzheimer's and Dementia</i> , 2020, 16, e040595.	0.4	0
36	Brain transcriptomes and plasma proteins reveal upregulation of a proinflammatory signature in APOE e4 carriers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041316.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Development of a robust and stable mass based spectrometry method for analysis of Alzheimer's disease biomarkers in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, e042035.	0.4	0
38	A pilot multiple crossover, randomized controlled trial of methylphenidate in mild cognitive impairment using standardized tests and daily brain games to track cognition. <i>Alzheimer's and Dementia</i> , 2020, 16, e043188.	0.4	0
39	Characterizing chromogranin and secretogranin proteoforms in dementia pathophysiology. <i>Alzheimer's and Dementia</i> , 2020, 16, e044624.	0.4	0
40	Plasma IL-12/IFN- γ axis predicts cognitive trajectories in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045497.	0.4	0
41	Plasma biomarkers of neuroinflammation and vascular injury predict cognitive decline in patients with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e046134.	0.4	2
42	Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. <i>Annals of Neurology</i> , 2020, 88, 513-525.	2.8	57
43	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020, 18, 140.	2.3	34
44	Clinical Trials and Tribulations in the COVID-19 Era. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 913-920.	0.6	19
45	Fuzzy Entropy Metrics for the Analysis of Biomedical Signals: Assessment and Comparison. <i>IEEE Access</i> , 2019, 7, 104833-104847.	2.6	29
46	Insulin and adipokine signaling and their cross-regulation in postmortem human brain. <i>Neurobiology of Aging</i> , 2019, 84, 119-130.	1.5	5
47	Brain IGFBP-5 modifies the relation of depressive symptoms to decline in cognition in older persons. <i>Journal of Affective Disorders</i> , 2019, 250, 313-318.	2.0	7
48	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7793-7798.	3.3	41
49	The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 752-762.	1.2	11
50	Task-related fMRI BOLD response to hyperinsulinemia in healthy older adults. <i>JCI Insight</i> , 2019, 4, .	2.3	8
51	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. <i>Nature Reviews Neurology</i> , 2018, 14, 168-181.	4.9	905
52	P279: CSF SMALL RNA BIOMARKERS FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P785.	0.4	0
53	P1274: A TARGETED MASS SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P387.	0.4	0
54	P3220: ULTRA-SENSITIVE DETECTION OF CENTRAL NERVOUS SYSTEM BIOMARKERS IN BLOOD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1155.	0.4	0

#	ARTICLE	IF	CITATIONS
55	P3â€³7: CLINICAL TRIAL DESIGN FOR A PHASE II, RANDOMIZED, PLACEBOâ€³CONTROLLED TRIAL OF AMX0035 IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1078.	0.4	0
56	Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. <i>Proteomes</i> , 2018, 6, 32.	1.7	52
57	Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease. <i>Annals of Neurology</i> , 2018, 84, 168-175.	2.8	11
58	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
59	Biomarkers in Alzheimerâ€™s, Frontotemporal, Lewy Body, and Vascular Dementias. <i>Focus (American J Psychiatry)</i> 110, 784-314.	0.4	0
60	The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimerâ€™s disease. <i>PLoS ONE</i> , 2018, 13, e0193707.	1.1	30
61	Higher C-Reactive Protein Levels Predict Postoperative Delirium in Older Patients Undergoing Major Elective Surgery: A Longitudinal Nested Case-Control Study. <i>Biological Psychiatry</i> , 2017, 81, 145-153.	0.7	100
62	Association of Cancer History with Alzheimerâ€™s Disease Dementia and Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 699-706.	1.2	35
63	Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination. , 2017, 13, 947-952.		35
64	Effects of the Insulin Sensitizer Metformin in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 107-113.	0.6	243
65	High C-Reactive Protein Predicts Delirium Incidence, Duration, and Feature Severity After Major Noncardiac Surgery. <i>Journal of the American Geriatrics Society</i> , 2017, 65, e109-e116.	1.3	93
66	Consensus Approaches to Identify Incident Dementia in Cohort Studies: Systematic Review and Approach in the Successful Aging after Elective Surgery Study. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1010-1018.e1.	1.2	11
67	P2â€³7: Brain Insulin Resistance and Alzheimer's Disease Neuropathology Among Older Autopsied Persons With and Without Diabetes. <i>Alzheimer's and Dementia</i> , 2016, 12, P653.	0.4	0
68	Demonstrated brain insulin resistance in Alzheimerâ€™s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <i>Journal of Clinical Investigation</i> , 2012, 122, 1316-1338.	3.9	1,431
69	Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	15